688687.SS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 10:00):

Beijing Kawin Technology Share-Holding Co., Ltd. engages in the development and production of pharmaceutical products primarily in the areas of liver diseases in China...

Stats
Dzisiejszy wolumen	3.89M
Średni wolumen	6.08M
Kapitalizacja rynkowa	5.29B
EPS	CNY0.130 ( 2024-04-30 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	44.54
ATR14	CNY0.0550 (0.17%)

Wolumen Korelacja

Długi: -0.23 (neutral)

Krótki: 0.85 (strong)

Signal:(50.943) Same movement expected

Beijing Kawin Technology Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Beijing Kawin Technology Korelacja - Waluta/Towar

-0.07
( neutral )

-0.01
( neutral )

0.00
( neutral )

-0.56
( weak negative )

0.28
( neutral )

0.59
( weak )

Beijing Kawin Technology Finanse

Annual	2023
Przychody:	CNY1.41B
Zysk brutto:	CNY1.18B (83.55 %)
EPS:	CNY0.700

FY	2023
Przychody:	CNY1.41B
Zysk brutto:	CNY1.18B (83.55 %)
EPS:	CNY0.700

FY	2022
Przychody:	CNY1.16B
Zysk brutto:	CNY1.00B (86.60 %)
EPS:	CNY0.500

FY	2021
Przychody:	CNY1.14B
Zysk brutto:	CNY1.00B (87.68 %)
EPS:	CNY0.660

Financial Reports:

No articles found.

Beijing Kawin Technology

Beijing Kawin Technology Share-Holding Co., Ltd. engages in the development and production of pharmaceutical products primarily in the areas of liver diseases in China. The company's products include recombinant human interferon alfa-2b injection and compound glycyrrhizin. It provides active pharmaceutical ingredients; clinical research services for biological product development, which include drug substancesfermentation and purification, drug productformulation, and analytical methods development; and contract manufacturing services. The company also serves customers in Pakistan, Colombia, Philippines, Vietnam, Russia, Cambodia, and others. It has strategic partnership with Legend Capital, Haitong Capital, and Cybernaut. The company was founded in 2008 and is based in Beijing, China.